about
Emerging therapeutic delivery capabilities and challenges utilizing enzyme/protein packaged bacterial vesiclesProtecting enzymatic function through directed packaging into bacterial outer membrane vesiclesVariable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary EmbolismImproving the targeting of therapeutics with single-domain antibodies.Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.Site-specific fab fragment biotinylation at the conserved nucleotide binding site for enhanced Ebola detection.Affinity purification of bacterial outer membrane vesicles (OMVs) utilizing a His-tag mutant.Nonchromatographic affinity precipitation method for the purification of bivalently active pharmaceutical antibodies from biological fluids.Conjugation of a reactive thiol at the nucleotide binding site for site-specific antibody functionalization.Directed Protein Packaging within Outer Membrane Vesicles from Escherichia coli: Design, Production and Purification.Printed Graphene Electrochemical Biosensors Fabricated by Inkjet Maskless Lithography for Rapid and Sensitive Detection of Organophosphates.Oriented surface immobilization of antibodies at the conserved nucleotide binding site for enhanced antigen detection.Disinhibiting neurons in the dorsomedial hypothalamus delays the onset of exertional fatigue and exhaustion in rats exercising in a warm environmentSmall-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targetingComparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivativesFibrin clot formation under diverse clotting conditions: Comparing turbidimetry and thromboelastography
P50
Q26801293-2F1BCD99-6F24-4866-8FED-AC9E73B07A7BQ27319739-5E53EC59-EC82-4762-90B9-A222A5F2A830Q35920702-6A2926D7-59DA-4086-9320-95D3784E3E56Q38675117-F2FE2F40-E2B4-49A7-899B-954E0A818D27Q38948139-7846BE3E-8B5A-43EE-AB48-0896BBCF06B7Q40169570-C4EF87E6-95BB-42C5-8DDA-B99AB046B385Q44867763-46803CA1-BBD8-4177-8BA2-1CE32196ECC3Q51062474-D0133F5D-8ADC-488D-9B6E-02369AF81FDDQ51074598-C708CA7E-5D06-4A05-BEF9-D73822ED10DDQ51089249-A18ACEA3-7157-4818-B8BA-137AB29146ECQ52879131-E96A6597-A30E-4864-A8CA-9ADAA8B80FA1Q53160891-14C5E9ED-4E5E-4BA6-850D-EB43BBFAE9A2Q64433351-545BE723-AA83-4A1E-9C2D-2D92716C5D94Q84886767-7FD534E9-E500-438A-B75D-EA96807D474BQ86506064-8A18F7E6-303A-4E98-BCE0-FAB9DF60F9E3Q92745639-02A88AFA-9054-4983-9AA3-62020EBD5A28
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Nathan J Alves
@en
Nathan J Alves
@nl
type
label
Nathan J Alves
@en
Nathan J Alves
@nl
prefLabel
Nathan J Alves
@en
Nathan J Alves
@nl
P31
P496
0000-0003-3816-5137